Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1862 results
August 2020
-
Press Release
Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis1… -
Press Release
Novartis announces Kymriah® meets primary endpoint at interim analysis of pivotal study in follicular lymphoma
Global ELARA trial demonstrated clinically meaningful benefit in patients with relapsed or refractory (r/r) follicular lymphoma (FL) as measured by complete response rate Kymriah previously… -
Press Release
Novartis Cosentyx® receives EU approval for first-line systemic treatment in pediatric psoriasis
EU approval is based on two Phase III studies showing Cosentyx® provides fast and strong skin clearance, along with significant improvement in quality of life and a favorable safety profile1 …
July 2020
-
Story Discovery
Collaborating to explore new gene regulation therapies
Novartis and Sangamo Therapeutics plan to pursue potential treatments for neurodevelopmental diseases.
-
Press Release
Novartis receives Piqray® approval in Europe – the first and only targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation
Piqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation, underscoring Novartis commitment to reimagining cancer care Approval based on SOLAR-1 Phase III trial… -
Featured News
Choice with Responsibility: Reimagining how we work
-
Press Release
Sandoz announces plans for joint investment to help strengthen future of antibiotics manufacturing in Europe
Sandoz and Austrian government announce joint plans to drive long-term competitiveness of European production for key antibiotics in Europe Planned combined investment of more than EUR 150… -
Press Release
New Novartis analysis shows wet AMD patients achieved sustained fluid control faster with Beovu® versus aflibercept
A post-hoc analysis of the HAWK and HARRIER trials presented at ASRS showed >=50% of patients achieved sustained retinal dryness by weeks 8 and 4 with Beovu and by weeks 12 and 8 with aflibercept… -
Story Discovery
Breaking a vicious cycle of inflammation
Novartis researchers aim to quash inflammation to treat chronic disease.
-
Press Release
Novartis Adakveo® receives positive CHMP opinion for the prevention of recurrent vaso-occlusive crises in patients with sickle cell disease
If approved, Adakveo would be the first targeted sickle cell disease therapy available for use in Europe CHMP opinion supported by data showing Adakveo significantly reduced the rate of vaso-… -
Featured News
Expanding CAR-T manufacturing in Europe to serve more patients
European Medicines Agency (EMA) recently approved two European Novartis sites for commercial CAR-T manufacturing.
-
Story Discovery
Helping clinical trial patients during a lockdown
Yan Zhao talks about how her team in China responded to an emerging public health crisis.